Education
About Us
Working with TipRanks
Follow Us
Neuronetics Inc (STIM)
NASDAQ:STIM
STIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $5.92
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.01M
Market Cap
$181.91M
Enterprise Value$50.25M
Total Cash (Recent Filing)$59.68M
Total Debt (Recent Filing)$62.47M
Price to Earnings (P/E)―
Beta1.95
Next Earnings
May 13, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding40,069,267
10 Day Avg. Volume2,020,207
30 Day Avg. Volume2,005,384
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.89
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$6.83Price Target Upside47.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Neuronetics News
PremiumCompany Announcements
Neuronetics’ Earnings Call: Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSTIM reported Q4 revenue of $22.5M, slightly ahead of the company’s preannouncement, indicating strong financial performance.
Merger BenefitsThe combination with Greenbrook is off to a good start, leading to a reaffirmation of the BUY recommendation with a target price increase to $8 from $5.
Bears Say
Operational ChallengesSTIM's second quarter reflected a top-line miss due to disruption from the Change Healthcare cybersecurity breach impacting the company's capital and treatment session sales.
---
Ownership Overview
8.09% Insiders
4.47% Mutual Funds
0.82% Other Institutional Investors
83.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.52 and its highest was $5.92 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $181.91M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is May 13, 2025 which is in 60 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Mar 04, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.088.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Undervalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 40,069,267 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went up 18.779%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
---
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.83 (47.52% Upside)
$6.83 (47.52% Upside)
Hedge Fund Trend
Decreased
By 2.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $666.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.32%
12-Months-Change
Fundamentals
Return on Equity
-138.47%
Trailing 12-Months
Asset Growth
15.21%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
---
STIM Company Deck
---
STIM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including revenue growth, a transformative acquisition, and successful program implementations. However, challenges such as decreased gross margins, increased operating expenses, and a net loss were also noted. The company is confident in its growth strategy for 2025.Read More>---
STIM Stock 12 Month Forecast
Average Price Target
$6.83
▲(47.52% Upside)
Technical Analysis
Best Analysts Covering STIM
1 Year
1 Year Success Rate
7/20 ratings generated profit
1 Year Average Return
+34.59%
reiterated a buy rating 10 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 35.00% of your transactions generating a profit, with an average return of +34.59% per trade.
---